The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
KRAS mutations and outcomes for patients with stage IV NSCLC treated with frontline platinum/pemetrexed based chemotherapy.
Benjamin Levy
Consultant or Advisory Role - Benjamin Levy
Honoraria - Lilly
Nagashree Seetharamu
No relevant relationships to disclose
Stacie Richardson
No relevant relationships to disclose
Daniel Jacob Becker
No relevant relationships to disclose
Walter Choi
No relevant relationships to disclose
Andrew Evans
No relevant relationships to disclose
Faiz Y. Bhora
No relevant relationships to disclose
Cliff P. Connery
No relevant relationships to disclose
Michael L. Grossbard
No relevant relationships to disclose
Abraham Chachoua
Consultant or Advisory Role - Abraham Chachoua
Honoraria - Lilly